Allergic rhinitis to mites - Workup and treatment;Diagnostik und therapie der milbenallergie

Allergologie

Volumn 38, Issue 2, 2015, Pages 70-82

  Klimek, L ^a   Sperl, A ^a   Raulf, M ^b  

^a Zentrum fur Rhinologie und Allergologie   (Germany)

^b INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

Author keywords

Allergen specific immunotherapy; Allergic rhinitis; Antihistamines; Mite allergy; Nasal glucocorticosteroids

Indexed keywords

ANTIHISTAMINIC AGENT; DECONGESTIVE AGENT; GLUCOCORTICOID; HISTAMINE RELEASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; AUDITORY TUBE DYSFUNCTION; CHRONIC SINUSITIS; COMORBIDITY; DERMATOPHAGOIDES; DRUG EFFICACY; DRUG SAFETY; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PERENNIAL RHINITIS; PREDATOR AVOIDANCE; REVIEW; SLEEP DISORDER;

EID: 84923163516     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/ALX01741     Document Type: Review

References (56)

1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJGlobal Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126: 466-476. CrossRef PubMed
2. Saloga J, et al. Allergologie-Handbuch: Grundlagen und klinische Praxis. Vol. 2. Stuttgart: Schattauer Verlag; 2011.
3. Becker S, Gröger M, Canis M, Pfrogner E, Kramer MF. Tropomyosin sensitization in house dust mite allergic patients. Eur Arch Otorhinolaryngol. 2012; 4: 269.
4. Rueff F, et al. Hauttests zur Diagnostik von allergischen Soforttyp-Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinischen Immunologie (DGAKI). Allergo J. 2010; 19: 402-415.
5. Riechelmann H, Bachert C, Goldchmidt O, et al. Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege. Allergo J. 2002; 11: 29-36.
6. Cazan D, Hackenberg B, Pfaar O, Klimek L. Die nasale Provokationstestung mit Allergenen. Methoden der klinischen Anwendung. Allergo J. 2013; 22: 189-200. CrossRef
7. Interdisziplinäre Arbeitsgruppe., Allergische Rhinitis" der Sektion HNO. Allergische Rhinokonjunktivitis: Leitlinie der Deutschen Gesellschaftfür Allergologie und klinische Immunologie (DGAI). Allergo J. 2003; 12: 182-194.
8. nd International Workshop. J Allergy Clin Immunol. 1992; 89: 1046-1060.
9. Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc. 2002; 77: 350-354. CrossRef PubMed
10. Stokes JR, Romero FA Jr, Allan RJ, Phillips PG, Hackman F, Misfeldt J, Casale TB. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012; 129: 409-412. CrossRef PubMed
11. Kay GG, Quig ME. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc. 2001; 22: 281-283. PubMed
12. Sádaba Díaz de Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc). 2011; 47: 251-262. CrossRef PubMed
13. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallelgroup study. Clin Exp Allergy. 2009; 39: 1338-1347. CrossRef PubMed
14. Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010; 65: 516-528. CrossRef PubMed
15. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009; 64: 158-165. CrossRef PubMed
16. Yamamoto H, Yamada T, Kubo S, Osawa Y, Kimura Y, Oh M, Susuki D, Takabayashi T, Okamoto M, Fujieda S. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. Allergy Asthma Proc. 2010; 31: 296-303. CrossRef PubMed
17. Perez I, et al. Rupatadine in allergic rhinitis: Pooled analysis of efficacy data. Allergy. 2002; 245
18. Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U, Petzold U. Azelastine nasal spray and desloratadine tablets in polleninduced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006; 22: 151-157. CrossRef PubMed
19. Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002; 89: 479-484. CrossRef PubMed
20. Kaliner MA, Berger WE, Ratner PH, Siegel CJ. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2011; 106 (Suppl): S6-S11. CrossRef PubMed
21. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006; 27: 413-426. CrossRef PubMed
22. Klimek L, Schendzielorz P, Högger P. Nasale Glukokortikosteroid-Therapie: Ein Update. Allergologie. 2010; 34: 307-318. CrossRef
23. Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol. 2009; 158: 164-173. CrossRef PubMed
24. Klimek L, Högger P, Pfaar O. Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis. Teil 1: Pathophysiologie, molekulare Grundlagen. HNO. 2012; 60: 611-617. CrossRef PubMed
25. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983; 220: 568-575. CrossRef PubMed
26. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006; 96: 779-786. CrossRef PubMed
27. Lehtimäki L, Petäys T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol. 2009; 149: 150-153. CrossRef PubMed
28. Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol. 2009; 102: 328-338. CrossRef PubMed
29. Prenner B, Anolik R, Danzig M, Yao R. Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc. 2009; 30: 263-269. CrossRef PubMed
30. Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010; 120: 1718-1723. CrossRef PubMed
31. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007; 62 (Suppl 85): 17-25. CrossRef PubMed
32. Dalal AA, Stanford R, Henry H, Borah B. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol. 2008; 101: 23-29. CrossRef PubMed
33. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, Ditta V, Martinelli N, Candore G, Mansueto P, Rini GB, Corrocher R, Caruso C. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mo-no- therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004; 34: 259-267. CrossRef PubMed
34. Anolik R; Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100: 264-271. CrossRef PubMed
35. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129: 1282-1289. CrossRef PubMed
36. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105: 168-173. CrossRef PubMed
37. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012; 33: 324-332. CrossRef PubMed
38. Kleine-Tebbe J, et al. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J. 2009; 508-537.
39. Brehler R, et al. Spezifische Immuntherapie - Indikation und Wirkungsweise. Dtsch Arztebl Int. 2013; 110: 148-158. PubMed
40. Blainey AD, Phillips MJ, Ollier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy. 1984; 39: 521-528. CrossRef PubMed
41. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 102 (Supplement): 558-562. CrossRef PubMed
42. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988; 18: 501-508. CrossRef PubMed
43. McHugh SM, Ewan PW. Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy. 1989; 19: 327-334. CrossRef PubMed
44. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol. 1990; 86: 521-531. CrossRef PubMed
45. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy. 2001; 56: 301-306. CrossRef PubMed
46. Pichler CE, Marquardsen A, Sparholt S, Løwenstein H, Bircher A, Bischof M, Pichler WJ. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy. 1997; 52: 274-283. CrossRef PubMed
47. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng J, Wu A, Zhong N. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006; 61: 191-197. CrossRef PubMed
48. Ameal A, Vega-Chicote JM, Fernández S, Miranda A, Carmona MJ, Rondón MC, Reina E, García-González JJ. Double-blind and placebocontrolled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. 2005; 60: 1178-1183. CrossRef PubMed
49. García-Robaina JC, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006; 118: 1026-1032. CrossRef PubMed
50. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006; 61: 843-848. CrossRef PubMed
51. Therapieallergene-Verordnung: Bundesgesetzblatt 13. November 2008, Guidelines on Allergen Products (EMEA/CHMP/BWP/304831/2007) v. 20. Nov. 2008. 2013.
52. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008; 102: 1371-1378. CrossRef PubMed
53. Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther. 2009; 9: 933-943. CrossRef PubMed
54. Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs. 2007; 21: 403-410. CrossRef PubMed
55. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010; 21 (1-Part-II): e160-e165. CrossRef PubMed
56. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39: 271-279. CrossRef PubMed